Protalix Biotherapeutics Inc (Protalix) develops and commercializes recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system (ProCellEx). The ProCellEx is a proprietary production system based on the company’s plant cell culture technology. ProCellEx enables the company to develop, express, and manufacture biologics and proprietary recombinant proteins for the treatment of Fabry disease, cystic fibrosis, and NETs related diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's R&D efforts focus on the development of its pipeline product for the treatment of Fabry disease, cystic fibrosis, and inflammatory diseases. Key technology includes ProCellEx protein expression system (ProCellEx). -Major pipeline products include PRX-110 (alidornase alfa), PRX-119(Long-Acting DNase I) and PRX-115 (uricase). In FY2022, the company spent US$29.3 million, on its R&D activities, which as a percentage of its revenue, stood at 61.6%. Consists of 80 patents in the US, Europe, Israel, and additional countries worldwide. It also had 30 pending patent applications.